Dementia and Movement Disorder Treatment Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, France - Size and Forecast 2024-2028

Published: Jan 2024 Pages: 177 SKU: IRTNTR73379

Dementia and Movement Disorder Treatment Market 2024-2028

The global dementia and movement disorder treatment market size is estimated to grow by USD 8.55 billion, at a CAGR of 7.28% between 2023 and 2028. 

In the global dementia and movement disorder treatment market, the risk of developing dementia increases exponentially with age, the CDC estimates that currently, approximately 200,000 people under age 65 in the US are living with younger-onset dementia, mainly Alzheimer's disease. The early onset of Alzheimer's disease symptoms is often called younger-onset dementia. The risk of the younger onset of Alzheimer's is four to five times higher in individuals with Down's syndrome. To offset the impact of younger onset among adults in the US, the US Department of Health and Human Services (HHS) created a special committee, the National Plan to Address Alzheimer's Disease, that takes care of individuals with Down's syndrome and younger-onset Alzheimer's by meeting the needs of American families currently facing these diseases. Furthermore, in addition to government initiatives, several other non-government initiatives have sprung up with individuals with younger-onset Alzheimer's, forming support networks to spread awareness about the symptoms of the disease and their unique needs. Thus, the growing efforts taken to increase public awareness regarding younger-onset dementia are anticipated to drive market growth during the forecast period.

Technavio has segmented the market into Application, Drug Class, and Geography 

  • The application segment includes movement disorders, progressive dementia, and progressive dementia with neurological abnormality (PDNA)
  • The drug class segment includes MAO inhibitors, acetylcholinesterase inhibitors, glutamate inhibitors, and others
  • The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our market research and growth report examines historical data from 2018-2022, besides analyzing market growth and forecasting. 

What will be the size of the Dementia and Movement Disorder Treatment Market During the Forecast Period?

To learn more about this report, Download Report Sample

Dementia and Movement Disorder Treatment Market Segmentation by Application, Drug Class, and Geography 

Application Analysis 

Movement disorders

The market share growth by the movement disorders segment will be significant during the forecast period. Movement disorders refer to a group of neurological conditions that primarily affect a person's ability to produce and control movements. Movement disorders can significantly impact an individual's ability to perform daily activities and lead a fulfilling life. Effective medications that can manage symptoms and enhance functional abilities are in demand to improve the quality of life for those affected.

Get a glance at the market contribution of various segments Download PDF Sample

The movement disorders segment was valued at USD 10.57 billion in 2018. Pharmaceutical companies, in collaboration with researchers and healthcare providers, are actively working on developing new medications and refining existing treatments to meet the growing demand for effective drugs that address various movement disorders. Emerging discoveries about movement disorder disease mechanisms are creating demand for medications that can more effectively intervene in the disease process, which is expected to propel the growth of the global dementia and movement disorder treatment market during the forecast period.

Drug Class Analysis 

MAO inhibitors

Monoamine oxidase inhibitors (MAOIs) are a class of drugs that block the actions of one or both MAO enzymes such as monoamine oxidase-A (MAO-A) and monoamine oxidase-B (MAO-B). MAO-B is a flavin adenine dinucleotide (FAD)-dependent mitochondrial enzyme. It is one of the two subtypes of the major monoamine metabolizing enzyme that regulates the levels of several chemicals in the brain, including the neurotransmitter dopamine. In addition, the literature on MAO-A inhibition in Parkinson's disease is comparatively scarce. However, various studies are being conducted to determine the role of this enzyme as a part of the therapeutic treatment of Parkinson's disease. Besides, MAO-B inhibitors such as selegiline, rasagiline, and safinamide are used to manage the early symptoms of the disease. Thus, the rising prevalence of Parkinson's disease and related disorders is expected to lead to an increase in the consumption of MAO inhibitors, thus driving market growth during the forecast period.

Acetylcholinesterase inhibitors

AChE is a hydrolytic enzyme that terminates acetylcholine (ACh)-mediated signal transmission by breaking down ACh in cholinergic synapses of the brain. ACh is a neurotransmitter that helps in the transmission of signals across nerve synapses. It is synthesized in nerve terminals and stored in vesicles. On receiving nerve impulses, nerve cells release ACh from vesicles, which reach the synaptic cleft and innervate postsynaptic and presynaptic receptors. The progressive death of cholinergic brain cells leads to dysfunction of cholinergic signal transmission and impairs the memory and behavior of a person, leading to Alzheimer's disease. In addition, AChE has been reported to be associated with senile plaques and other hallmarks of Alzheimer's disease. Thus, maintenance of adequate levels of choline by inhibiting AChE is a viable treatment approach for the management of the disease. AChE inhibitors act by inhibiting AChE in a competitive or non-competitive manner. Thus, such studies are expected to have a favorable impact on the growth of the global dementia and movement disorder treatment market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 47% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America dominated the global dementia and movement disorder treatment market, with the US and Canada being significant revenue contributors to the market. The presence of global key market players in the US is driving the market growth. Furthermore, factors such as the advanced healthcare system and the patient-assistance programs by the Patient Access Network (PAN) Foundation in the US are expected to drive market growth in the region during the forecast period. Additionally, Increasing investments will bring about substantial growth opportunities in the market. Thus, the rise in government interest in drug development for dementia and movement disorders is expected to drive market growth in North America during the forecast period.

Buy Full Report Now

Key Dementia and Movement Disorder Treatment Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

AbbVie Inc.: The company offers treatment for dementia and movement disorder under the brand names of Namenda and Duopa, where the initial dosage is 5 mg once daily and are available in the form of tablets of 5 mg and 10 mg.

  • Acorda Therapeutics Inc.
  • Amneal Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • Biogen Inc.
  • Eisai Co. Ltd.
  • GlaxoSmithKline Plc
  • H Lundbeck AS
  • Johnson and Johnson
  • Kirin Holdings Co. Ltd.
  • Lannett Co. Inc.
  • Merck and Co. Inc.
  • Neurocrine Biosciences Inc.
  • Novartis AG
  • Organon and Co.
  • Orion Pharma Ltd.
  • Otsuka Holdings Co. Ltd.
  • Supernus Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Dementia and Movement Disorder Treatment Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Dementia and Movement Disorder Treatment Market Drivers

The rising prevalence of target diseases is the key factor driving market growth.  According to WHO, in September 2021, more than 55 million people were affected by dementia worldwide, and nearly 10 million new cases are diagnosed every year globally. In addition, as per WHO, Alzheimer's disease is one of the most common forms of dementia and accounts for 60%-70% of the cases. The disease is prevalent in people aged 65 years or above, and women are more susceptible to it than men. Neuronal loss associated with Alzheimer's disease reduces brain size and results in the deposition of debris from the dead and dying neurons in the brain.

Furthermore, some other types of dementia include Parkinson's disease, Lewy body dementia, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, Huntington's disease, Wernicke-Korsakoff syndrome, and Binswanger's disease. Consequently, the high requirement for the treatment of different types of dementia will propel the demand for treatment drugs, thereby driving the growth of the global dementia and movement disorder treatment market during the forecast period.

Significant Dementia and Movement Disorder Treatment Market Trends

Advances in biomedical science is the primary trend shaping market growth. Modern techniques like bioinformatics, molecular targeting, nanotechnology, and personalized medicine facilitated drug development in the area of neurodegenerative disorders, including dementia. Bioinformatics employs the use of a mathematical model to enhance the understanding of human systems. The currently available neuroimaging and cerebrospinal fluid-based diagnoses used for detecting Alzheimer's disease are costly. Therefore, bioinformatics is being used to improve the diagnosis of Alzheimer's disease.

Additionally, the availability of enhanced biotechnological tools such as ribonucleic acid interference (RNAi) and a better understanding of the human genome has led to the development of targeted therapies for patients. Besides, ongoing research trials utilizing these modern technologies underscore the positive impact of biomedical science advances on the global dementia and movement disorder treatment market in the forecast period, aligning with current market trends and analysis.

Major Dementia and Movement Disorder Treatment Market Challenges

Failure rates of drugs in clinical trials is a challenge that affects market growth. The development of dementia therapeutics and their clinical trials remain vulnerable to challenges, which further hinder the development of curative therapies for the treatment of dementia. There are currently four drugs that are approved and being used for the symptomatic treatment of Alzheimer's disease, which include donepezil, rivastigmine, galantamine, and memantine. However, several drugs identified as potential therapies for Alzheimer's disease failed in clinical trials. 

Additionally, failure in clinical trials often leads to discontinuation of drugs and, therefore, wastage of revenue spent on the initial development of the drug. Failure in clinical trials can also lead to the termination of strategic industry partnerships, which are otherwise essential to boost R&D activities in the market. Hence, such factors are likely to hinder the growth of the global dementia and movement disorder treatment market during the forecast period.

Buy Now Full Report

Key Dementia and Movement Disorder Treatment Market Customer Landscape

The market report includes the adoption lifecycle of the market forecast, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market analysis and report also include key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Dementia and Movement Disorder Treatment Market Customer Landscape

Segment Overview

The dementia and movement disorder treatment market report forecasts market growth analysis by revenue at global, regional & country levels and provides an analysis of the latest market growth and trends from 2018 to 2028. 

  • Application Outlook
    • Movement disorders
    • Progressive dementia
    • Progressive dementia with neurological abnormality (PDNA)
  • Drug Class Outlook
    • MAO inhibitors
    • Acetylcholinesterase inhibitors
    • Glutamate inhibitors
    • Others
  • Region Outlook
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • APAC
      • China
      • India
    • Rest of World (ROW)
      • Argentina
      • Australia
      • Brazil

Dementia and Movement Disorder Treatment Market Scope

Report Coverage

Details

Page number

177

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 7.28%

Market Growth 2024-2028

USD 8.55 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

6.63

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 47%

Key countries

US, Canada, Germany, UK, and France

Competitive landscape

 Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Acorda Therapeutics Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Biogen Inc., Eisai Co. Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson, Kirin Holdings Co. Ltd., Lannett Co. Inc., Merck and Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Organon and Co., Orion Pharma Ltd., Otsuka Holdings Co. Ltd., Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., and UCB SA

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. 

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Dementia and Movement Disorder Treatment Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the dementia and movement disorder treatment market between 2024 and 2028
  • Precise estimation of the dementia and movement disorder treatment market size and its contribution to the market in focus on the parent market
  • Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies' position and classification
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of dementia and movement disorder treatment market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Drug Class
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global dementia and movement disorder treatment market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global dementia and movement disorder treatment market 2018 - 2022 ($ billion)
    • 4.2 Application Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – Application Segment 2018 - 2022 ($ billion)
    • 4.3 Drug Class Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Drug Class Segment 2018 - 2022 ($ billion)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Application

    • 6.1 Market segments
      • Exhibit 30: Chart on Application - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on Application - Market share 2023-2028 (%)
    • 6.2 Comparison by Application
      • Exhibit 32: Chart on Comparison by Application
      • Exhibit 33: Data Table on Comparison by Application
    • 6.3 Movement disorders - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Movement disorders - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 35: Data Table on Movement disorders - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 36: Chart on Movement disorders - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Movement disorders - Year-over-year growth 2023-2028 (%)
    • 6.4 Progressive dementia - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Progressive dementia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 39: Data Table on Progressive dementia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 40: Chart on Progressive dementia - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Progressive dementia - Year-over-year growth 2023-2028 (%)
    • 6.5 Progressive dementia with neurological abnormality (PDNA) - Market size and forecast 2023-2028
      • Exhibit 42: Chart on Progressive dementia with neurological abnormality (PDNA) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 43: Data Table on Progressive dementia with neurological abnormality (PDNA) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 44: Chart on Progressive dementia with neurological abnormality (PDNA) - Year-over-year growth 2023-2028 (%)
      • Exhibit 45: Data Table on Progressive dementia with neurological abnormality (PDNA) - Year-over-year growth 2023-2028 (%)
    • 6.6 Market opportunity by Application
      • Exhibit 46: Market opportunity by Application ($ billion)
      • Exhibit 47: Data Table on Market opportunity by Application ($ billion)

    7 Market Segmentation by Drug Class

    • 7.1 Market segments
      • Exhibit 48: Chart on Drug Class - Market share 2023-2028 (%)
      • Exhibit 49: Data Table on Drug Class - Market share 2023-2028 (%)
    • 7.2 Comparison by Drug Class
      • Exhibit 50: Chart on Comparison by Drug Class
      • Exhibit 51: Data Table on Comparison by Drug Class
    • 7.3 MAO inhibitors - Market size and forecast 2023-2028
      • Exhibit 52: Chart on MAO inhibitors - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 53: Data Table on MAO inhibitors - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 54: Chart on MAO inhibitors - Year-over-year growth 2023-2028 (%)
      • Exhibit 55: Data Table on MAO inhibitors - Year-over-year growth 2023-2028 (%)
    • 7.4 Acetylcholinesterase inhibitors - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Acetylcholinesterase inhibitors - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 57: Data Table on Acetylcholinesterase inhibitors - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 58: Chart on Acetylcholinesterase inhibitors - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Acetylcholinesterase inhibitors - Year-over-year growth 2023-2028 (%)
    • 7.5 Glutamate inhibitors - Market size and forecast 2023-2028
      • Exhibit 60: Chart on Glutamate inhibitors - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 61: Data Table on Glutamate inhibitors - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 62: Chart on Glutamate inhibitors - Year-over-year growth 2023-2028 (%)
      • Exhibit 63: Data Table on Glutamate inhibitors - Year-over-year growth 2023-2028 (%)
    • 7.6 Others - Market size and forecast 2023-2028
      • Exhibit 64: Chart on Others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 65: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 66: Chart on Others - Year-over-year growth 2023-2028 (%)
      • Exhibit 67: Data Table on Others - Year-over-year growth 2023-2028 (%)
    • 7.7 Market opportunity by Drug Class
      • Exhibit 68: Market opportunity by Drug Class ($ billion)
      • Exhibit 69: Data Table on Market opportunity by Drug Class ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 71: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 72: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 73: Chart on Geographic comparison
      • Exhibit 74: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 Germany - Market size and forecast 2023-2028
      • Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.9 UK - Market size and forecast 2023-2028
      • Exhibit 99: Chart on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 100: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 101: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.10 Canada - Market size and forecast 2023-2028
      • Exhibit 103: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 104: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 105: Chart on Canada - Year-over-year growth 2023-2028 (%)
      • Exhibit 106: Data Table on Canada - Year-over-year growth 2023-2028 (%)
    • 9.11 France - Market size and forecast 2023-2028
      • Exhibit 107: Chart on France - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 108: Data Table on France - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 109: Chart on France - Year-over-year growth 2023-2028 (%)
      • Exhibit 110: Data Table on France - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 111: Market opportunity by geography ($ billion)
      • Exhibit 112: Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 113: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 115: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 116: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 117: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 118: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 119: AbbVie Inc. - Overview
              • Exhibit 120: AbbVie Inc. - Product / Service
              • Exhibit 121: AbbVie Inc. - Key news
              • Exhibit 122: AbbVie Inc. - Key offerings
            • 12.4 Acorda Therapeutics Inc.
              • Exhibit 123: Acorda Therapeutics Inc. - Overview
              • Exhibit 124: Acorda Therapeutics Inc. - Product / Service
              • Exhibit 125: Acorda Therapeutics Inc. - Key offerings
            • 12.5 Amneal Pharmaceuticals Inc.
              • Exhibit 126: Amneal Pharmaceuticals Inc. - Overview
              • Exhibit 127: Amneal Pharmaceuticals Inc. - Business segments
              • Exhibit 128: Amneal Pharmaceuticals Inc. - Key news
              • Exhibit 129: Amneal Pharmaceuticals Inc. - Key offerings
              • Exhibit 130: Amneal Pharmaceuticals Inc. - Segment focus
            • 12.6 Biogen Inc.
              • Exhibit 131: Biogen Inc. - Overview
              • Exhibit 132: Biogen Inc. - Product / Service
              • Exhibit 133: Biogen Inc. - Key offerings
            • 12.7 Eisai Co. Ltd.
              • Exhibit 134: Eisai Co. Ltd. - Overview
              • Exhibit 135: Eisai Co. Ltd. - Business segments
              • Exhibit 136: Eisai Co. Ltd. - Key offerings
              • Exhibit 137: Eisai Co. Ltd. - Segment focus
            • 12.8 H Lundbeck AS
              • Exhibit 138: H Lundbeck AS - Overview
              • Exhibit 139: H Lundbeck AS - Product / Service
              • Exhibit 140: H Lundbeck AS - Key offerings
            • 12.9 Johnson and Johnson
              • Exhibit 141: Johnson and Johnson - Overview
              • Exhibit 142: Johnson and Johnson - Business segments
              • Exhibit 143: Johnson and Johnson - Key news
              • Exhibit 144: Johnson and Johnson - Key offerings
              • Exhibit 145: Johnson and Johnson - Segment focus
            • 12.10 Kirin Holdings Co. Ltd.
              • Exhibit 146: Kirin Holdings Co. Ltd. - Overview
              • Exhibit 147: Kirin Holdings Co. Ltd. - Business segments
              • Exhibit 148: Kirin Holdings Co. Ltd. - Key offerings
              • Exhibit 149: Kirin Holdings Co. Ltd. - Segment focus
            • 12.11 Lannett Co. Inc.
              • Exhibit 150: Lannett Co. Inc. - Overview
              • Exhibit 151: Lannett Co. Inc. - Product / Service
              • Exhibit 152: Lannett Co. Inc. - Key offerings
            • 12.12 Merck and Co. Inc.
              • Exhibit 153: Merck and Co. Inc. - Overview
              • Exhibit 154: Merck and Co. Inc. - Business segments
              • Exhibit 155: Merck and Co. Inc. - Key news
              • Exhibit 156: Merck and Co. Inc. - Key offerings
              • Exhibit 157: Merck and Co. Inc. - Segment focus
            • 12.13 Novartis AG
              • Exhibit 158: Novartis AG - Overview
              • Exhibit 159: Novartis AG - Business segments
              • Exhibit 160: Novartis AG - Key offerings
              • Exhibit 161: Novartis AG - Segment focus
            • 12.14 Otsuka Holdings Co. Ltd.
              • Exhibit 162: Otsuka Holdings Co. Ltd. - Overview
              • Exhibit 163: Otsuka Holdings Co. Ltd. - Business segments
              • Exhibit 164: Otsuka Holdings Co. Ltd. - Key offerings
              • Exhibit 165: Otsuka Holdings Co. Ltd. - Segment focus
            • 12.15 Supernus Pharmaceuticals Inc.
              • Exhibit 166: Supernus Pharmaceuticals Inc. - Overview
              • Exhibit 167: Supernus Pharmaceuticals Inc. - Product / Service
              • Exhibit 168: Supernus Pharmaceuticals Inc. - Key offerings
            • 12.16 Teva Pharmaceutical Industries Ltd.
              • Exhibit 169: Teva Pharmaceutical Industries Ltd. - Overview
              • Exhibit 170: Teva Pharmaceutical Industries Ltd. - Business segments
              • Exhibit 171: Teva Pharmaceutical Industries Ltd. - Key news
              • Exhibit 172: Teva Pharmaceutical Industries Ltd. - Key offerings
              • Exhibit 173: Teva Pharmaceutical Industries Ltd. - Segment focus
            • 12.17 UCB SA
              • Exhibit 174: UCB SA - Overview
              • Exhibit 175: UCB SA - Product / Service
              • Exhibit 176: UCB SA - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 177: Inclusions checklist
                • Exhibit 178: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 179: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 180: Research methodology
                • Exhibit 181: Validation techniques employed for market sizing
                • Exhibit 182: Information sources
              • 13.5 List of abbreviations
                • Exhibit 183: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              dementia and movement disorder treatment market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis